BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27560551)

  • 1. Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma.
    Alhasan SF; Haugk B; Ogle LF; Beale GS; Long A; Burt AD; Tiniakos D; Televantou D; Coxon F; Newell DR; Charnley R; Reeves HL
    Br J Cancer; 2016 Sep; 115(7):797-804. PubMed ID: 27560551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
    Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
    Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraneoplastic Ma Antigen-Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma.
    Kuwae Y; Kakehashi A; Wakasa K; Wei M; Yamano S; Ishii N; Ohsawa M; Wanibuchi H
    Pancreas; 2015 Jan; 44(1):106-15. PubMed ID: 25251443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
    World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.
    Lenz J; Karasek P; Jarkovsky J; Muckova K; Dite P; Kala Z; Veselska R; Hermanova M
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):389-96. PubMed ID: 22187705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impact of Cell Division Cycle Associated 2 Expression on Pancreatic Ductal Adenocarcinoma.
    Wang MY; Niu ZY; Gao XG; Zhou L; Liao Q; Zhao YP
    Chin Med Sci J; 2016 Sep; 31(3):149-154. PubMed ID: 27733221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma.
    Yang L; Yang Z; Li D; Liu Z; Zou Q; Yuan Y; Xu H
    Pathol Oncol Res; 2018 Oct; 24(4):899-906. PubMed ID: 28921449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jagged1 and DLL4 expressions in benign and malignant pancreatic lesions and their clinicopathological significance.
    Huang SF; Yang ZL; Li DQ; Liu ZY; Wang CW; Miao XY; Zou Q; Yuan Y
    Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):640-646. PubMed ID: 27919854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 accumulation confers prognostic information in resectable adenocarcinomas with ductal but not with intestinal differentiation in the pancreatic head.
    Bergan A; Gladhaug IP; Schjolberg A; Bergan AB; Clausen OP
    Int J Oncol; 2000 Nov; 17(5):921-6. PubMed ID: 11029493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
    Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
    Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastric- and intestinal-type marker expression in invasive ductal adenocarcinoma of the pancreas.
    Takano Y; Ohike N; Tajiri T; Asonuma K; Harada K; Takahashi H; Morohoshi T
    Hepatobiliary Pancreat Dis Int; 2012 Aug; 11(4):424-8. PubMed ID: 22893471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
    Yu R; Li C; Lin X; Chen Q; Li J; Song L; Lin L; Liu J; Zhang Y; Kong W; Ouyang X; Chen X
    Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
    Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
    Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues.
    Takadate T; Onogawa T; Fukuda T; Motoi F; Suzuki T; Fujii K; Kihara M; Mikami S; Bando Y; Maeda S; Ishida K; Minowa T; Hanagata N; Ohtsuka H; Katayose Y; Egawa S; Nishimura T; Unno M
    Int J Cancer; 2013 Mar; 132(6):1368-82. PubMed ID: 22915188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survivin expression and serum levels in pancreatic cancer.
    Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
    World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
    BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
    Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
    Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC.
    Gundlach JP; Hauser C; Schlegel FM; Böger C; Röder C; Röcken C; Becker T; Egberts JH; Kalthoff H; Trauzold A
    BMC Cancer; 2018 Jul; 18(1):777. PubMed ID: 30064384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.